Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials-Reference-Cited by-同舟云学术

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

Published:2018-05-24 Issue:12 Volume:118 Page:1571-1579
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Yokota Tomoya,Bendell Johanna,LoRusso Patricia,Tsushima Takahiro,Desai Ved,Kenmotsu Hirotsugu,Watanabe Junichiro,Ono Akira,Murugesan Bhavani,Silva Joseph,Naito Tateaki,Greenberg Jonathan,Kumar Prasanna,Wang Yibin,Jikoh Takahiro,Shiga Ryota,Hyman David M.,Ho Alan Loh,Spriggs David R.,Schwartz Gary K.,Gounder Mrinal M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0102-1.pdf

Reference58 articles.

1. Prowell, T. M., Theoret, M. R. & Pazdur, R. Seamless oncology-drug development. N. Engl. J. Med. 374, 2001–2003 (2016).

2. Malik, S. M. et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin. Cancer Res. 20, 2029–2034 (2014).

3. Khozin, S. et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin. Cancer Res. 21, 2436–2439 (2015).

4. Khozin, S. et al. Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer. Clin. Cancer Res. 23, 2131–2135 (2017).

5. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumours to PD-1 blockade. Science 357, 409–413 (2017).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bibliometric analysis of the application of the PI3K-AKT-mTOR signaling pathway in cancer;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-05-06

2. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review;Medical Oncology;2021-01

3. Insights Into Breast Cancer in the East vs the West;JAMA Oncology;2019-10-01